Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases

Pharmacogenomics Journal

Volumn 13, Issue 4, 2013, Pages 297-305

  Prieto Perez R ^a   Cabaleiro, T ^a   Dauden E ^a   Abad Santos, F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adalimumab; Etanercept; Gene polymorphisms; Infliximab; Psoriasis

Indexed keywords

ADALIMUMAB; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CROHN DISEASE; CYTOKINE RESPONSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IL10 GENE; IL12B GENE; IL13 GENE; IL18 GENE; IL1A GENE; IL21 GENE; IL23R GENE; IMMUNOPATHOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TNF ALPHA GENE;

EID: 84881121796     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.53     Document Type: Review

References (126)

1. Bak RO, Mikkelsen JG. Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci 2010; 17: 53.
2. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13(Spec No 1): R43-R55.
3. Chandran V. Genetics of psoriasis and psoriatic arthritis. Indian J Dermatol 2010; 55: 151-156.
4. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: J314-J321.
5. Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends Genet 2010; 26: 415-423.
6. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206.
7. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290.
8. Enerback C, Martinsson T, Inerot A, Wahlstrom J, Enlund F, Yhr M et al. Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequencespecific primers (PCR-SSP). Acta Derm Venereol 1997; 77: 273-276.
9. Peddle L, Butt C, Snelgrove T, Rahman P. Interleukin (IL) 1alpha, IL1beta, IL receptor antagonist, and IL10 polymorphisms in psoriatic arthritis. Ann Rheum Dis 2005; 64: 1093-1094.
10. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-D906.
11. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64: 65-68.
12. EMA (European Medicines Agency). Committee for Medicinal Products for human use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. London 2004, Doc. ref. CHMP/EWP/2454/02. corr.
13. Smith CH, Anstey AV, JNWN Barker, Burden AD, Chalmers RJG, Chandler AD et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
14. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.
15. Lipsky PE. Harrison's Rheumatology. In: Rheumatoid Arthritis. Fauci A, Langford C (eds). Section II. Disorders of immune-mediated injury, second edn. Mc Graw-Hill, 2010.
16. Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA 2001; 285: 643-647.
17. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3545.
18. Bathon J. Anti-TNF therapy for the Treatment of Rheumatoid Arthritis 1999-2010, Avaliable from http://www.hopkinsarthritis.org/arthritis-info/ rheumatoidarthritis/ra-treatment/anti-tnf-therapy-for-ra/.
19. Panes J, Salas A. Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel diseases. Gut 2009; 58: 898-900.
20. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58: 1152-1167.
21. O'Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev 2011; 7: 718-732.
22. Takayanagi H. How does the immune system break and protect bone? Science (on line version). 2002, pp 1095-9203; ISSN 0036-8075. Available at: http://site/feature/data/pharmacia/2002/takayanagi.xhtml.
23. Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith Jr MF, Foley E et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999; 162: 6829-6835.
24. Smith RL, Warren RB, Eyre S, Ho P, Ke X, Young HS et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol 2008; 128: 1325-1327.
25. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H et al. Interleukin-12 p40 gene (IL12B) 30-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30: 161-166.
26. Wu Y, Lu Z, Chen Y, Xue F, Chen X, Zheng J. Replication of association between interleukin-23 receptor (IL-23R) and its ligand (IL-12B) polymorphisms and psoriasis in the Chinese Han population. Hum Immunol 2010; 71: 1255-1258.
27. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008; 128: 1653-1661.
28. van der Heide F, Nolte IM, Kleibeuker JH, Wijmenga C, Dijkstra G, Weersma RK. Differences in genetic background between active smokers, passive smokers, and non-smokers with Crohn's disease. Am J Gastroenterol 2010; 105: 1165-1172.
29. Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58: 3705-3709.
30. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
31. Li Y, Begovich AB. Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. Semin Immunol 2009; 21: 318-327.
32. Varade J, Ramon Lamas J, Rodriguez L, Fernandez-Arquero M, Loza-Santamaria E, Jover JA et al. IL23R and IL12B genes: susceptibility analysis in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1230-1232.
33. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126: 121-136.
34. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract 2009; 5: 83-91.
35. Chang M, Li Y, Yan C, Callis-Duffin KP, Matsunami N, Garcia VE et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun 2008; 9: 176-181.
36. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
37. Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R et al. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol 2009; 129: 2777-2783.
38. Eder L, Chandran V, Pellett F, Pollock R, Shanmugarajah S, Rosen CF et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2011; 70: 1594-1598.
39. Bowes J, Eyre S, Flynn E, Ho P, Salah S, Warren RB et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis 2011; 70: 1016-1019.
40. Li Y, Chang M, Schrodi SJ, Callis-Duffin KP, Matsunami N, Civello D et al. The 5q31 variants associated with psoriasis and Crohn's disease are distinct. Hum Mol Genet 2008; 17: 2978-2985.
41. Marinou I, Till SH, Moore DJ, Wilson AG. Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis. Arthritis Res Ther 2008; 10: R80.
42. Garcia VE, Chang M, Brandon R, Li Y, Matsunami N, Callis-Duffin KP et al. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun 2008; 9: 546-555.
43. Hinks A, Martin P, Flynn E, Eyre S, Packham J, Barton A et al. Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis Res Ther 2011; 13: R12.
44. Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009; 36: 137-140.
45. Huffmeier U, Lascorz J, Bohm B, Lohmann J, Wendler J, Mossner R et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129: 355-358.
46. Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A et al. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients. Dig Liver Dis 2008; 40: 867-873.
47. Raelson JV, Little RD, Ruether A, Fournier H, Paquin B, Van Eerdewegh P et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci USA 2007; 104: 14747-14752.
48. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. A genomewide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
49. Park JH, Kim YJ, Park BL, Bae JS, Shin HD, Bae SC. Lack of association between interleukin 23 receptor gene polymorphisms and rheumatoid arthritis susceptibility. Rheumatol Int 2009; 29: 781-786.
50. Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008; 67: 248-250.
51. Reich K, Mossner R, Konig IR, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002; 118: 155-163.
52. Tolusso B, Pietrapertosa D, Morelli A, De Santis M, Gremese E, Farina G et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006; 7: 683-695.
53. Ravindran JS, Owen P, Lagan A, Lewis J, Korendowych E, Welsh K et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology 2004; 43: 22-26.
54. Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54: 2321-2325.
55. Bowes J, Ho P, Flynn E, Salah S, McHugh N, FitzGerald O et al. Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. Ann Rheum Dis 2011; 71: 313-314.
56. Harrison P, Pointon JJ, Chapman K, Roddam A, Wordsworth BP. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Rheumatology 2008; 47: 1768-1770.
57. Celik Y, Dagli U, Kilic MY, Toruner M, Ozen SC, Ozkan M et al. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 559-565.
58. Ferreira AC, Almeida S, Tavares M, Canedo P, Pereira F, Regalo G et al. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. Inflamm Bowel Dis 2005; 11: 331-339.
59. Nemetz A, Nosti-Escanilla MP, Molnar T, Kope A, Kovacs A, Feher J et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999; 49: 527-531.
60. Morales-Lara MJ, Canete JD, Torres-Moreno D, Hernandez MV, Pedrero F, Celis R et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012; 79: 591-596.
61. Buchs N, di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001; 2: 222-228.
62. Wang AH, Lam WJ, Han DY, Ding Y, Hu R, Fraser AG et al. The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol 2011; 72: 431-435.
63. Andersen V, Ernst A, Christensen J, Ostergaard M, Jacobsen BA, Tjonneland A et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet 2010; 11: 82.
64. Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K et al. Tumour necrosis factor-alpha polymorphism and the HLA-Cw0602 allele in psoriatic arthritis. Rheumatology 2002; 41: 525-530.
65. Baran W, Szepietowski JC, Mazur G, Baran E. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 2008; 88: 113-116.
66. Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun 2003; 4: 455-457.
67. Settin A, Hassan H, El-Baz R, Hassan T. Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatovenerol Alp Panonica Adriat 2009; 18: 105-112.
68. Craven NM, Jackson CW, Kirby B, Perrey C, Pravica V, Hutchinson IV et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001; 144: 849-853.
69. Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J et al. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis 2005; 11: 739-743.
70. Zhang J, Zhang Y, Jin J, Li M, Xie K, Wen C et al. The -1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: a meta-analysis. Cytokine 2011; 56: 351-355.
71. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mol Biol Rep 2012; 39: 81-87.
72. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010; 29: 48-52.
73. Schrodi SJ. Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. Expert Rev Clin Immunol 2008; 4: 565-571.
74. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81: 1284-1288.
75. Marquez A, Orozco G, Martinez A, Palomino-Morales R, Fernandez-Arquero M, Mendoza JL et al. Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1968-1975.
76. Hollis-Moffatt JE, Gearry RB, Barclay ML, Merriman TR, Roberts RL. Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease. Am J Gastroenterol 2010; 105: 1204-1205author reply 1206-1207.
77. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-565.
78. Li C, Wang G, Gao Y, Liu L, Gao T. TNF-alpha gene promoter -238G4A and - 308G4A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol 2007; 127: 1886-1892.
79. Mossner R, Kingo K, Kleensang A, Kruger U, Konig IR, Silm H et al. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 2005; 124: 282-284.
80. Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellett F et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006; 65: 919-923.
81. Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48: 1408-1413.
82. Reich K, Huffmeier U, Konig IR, Lascorz J, Lohmann J, Wendler J et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56: 2056-2064.
83. Reich K, Westphal G, Schulz T, Muller M, Zipprich S, Fuchs T et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999; 113: 214-220.
84. Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M, Glen J, Rebala K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol 2007; 157: 165-167.
85. Arias AI, Giles B, Eiermann TH, Sterry W, Pandey JP. Tumor necrosis factor-alpha gene polymorphism in psoriasis. Exp Clin Immunogenet 1997; 14: 118-122.
86. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000; 114: 1180-1183.
87. Kim TG, Pyo CW, Hur SS, Kim YK, Hwang HY, Youn JI et al. Polymorphisms of tumor necrosis factor (TNF) alpha and beta genes in Korean patients with psoriasis. Arch Dermatol Res 2003; 295: 8-13.
88. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 2007; 8: 761-773.
89. Nemec P, Pavkova-Goldbergova M, Stouracova M, Vasku A, Soucek M, Gatterova J. Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 2008; 27: 59-65.
90. Ingegnoli F, Favalli EG, Meroni PL. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. Autoimmun Rev 2011; 10: 460-463.
91. Fabris M, Di Poi E, Sacco S, Damante G, Sinigaglia L, Ferraccioli G. [TNF-alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNFalpha agents: preliminary results]. Reumatismo 2002; 54: 19-26.
92. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004; 50: 2750-2756.
93. Lee YH, Ji JD, Bae SC, Song GG. Associations between tumor necrosis factoralpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2010; 37: 740-746.
94. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849-1852.
95. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 478-484.
96. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D et al. Influence of -308A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 57: 1426-1430.
97. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factoralpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007; 46: 93-96.
98. Ozeki T, Furuya Y, Nagano C, Matsui C, Takayanagi R, Yokoyama H et al. Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 50-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. Mutat Res 2006; 602: 170-174.
99. Vasilopoulos Y, Manolika M. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in Greek population. Mol Diagn Ther 2012; 16: 29-34.
100. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 2008; 27: 765-770.
101. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303-310.
102. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127-136.
103. Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF et al. Can tumor necrosis factor receptor II gene 676T4G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int 2008; 28: 901-908.
104. Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B, Schaeverbeke T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008; 26: 340-342.
105. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med 2010; 10: 177-183.
106. Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011; 70: 1641-1644.
107. Tejasvi T. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132: 596-600.
108. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62: 1849-1861.
109. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-1355.
110. Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics 2006; 16: 369-373.
111. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1547-1552.
112. Lee YH, Ji JD, Song GG. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. J Rheumatol 2008; 35: 2129-2135.
113. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52: 2693-2696.
114. Nishio S, Yamamoto T, Kaneko K, Tanaka-Matsumoto N, Muraoka S, Kaburaki M et al. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol 2009; 19: 329-333.
115. Suzuki T, Tsutsumi A, Suzuki H, Suzuki E, Sugihara M, Muraki Y et al. Tristetraprolin (TTP) gene polymorphisms in patients with rheumatoid arthritis and healthy individuals. Mod Rheumatol 2008; 18: 472-479.
116. Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW et al. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 2009; 19: 319-323.
117. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69: 1315-1320.
118. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14: 575-581.
119. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 526-529.
120. Nair RP, Stuart PE, Kullavanijaya P, Tejasvi T, Voorhees JJ, Elder JT. Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. Arch Dermatol Res 2010; 302: 139-143.
121. O'Rielly DD, Rahman P. Evaluation for psoriatic arthritis in dermatology clinics. J Cutan Med Surg 2009; 13: S88-S92.
122. Zheng HF, Zuo XB, Lu WS, Li Y, Cheng H, Zhu KJ et al. Variants in MHC, LCE and IL12B have epistatic effects on psoriasis risk in Chinese population. J Dermatol Sci 2011; 61: 124-128.
123. Web page Hapmap http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap 3r3-B36/#search.
124. Gallo E, Cabaleiro T, Román M, Abad-Santos F, Daudén E. Study of genetic polymorphisms in the tumor necrosis factor a promoter region in Spanish patients with psoriasis. Actas Dermosifiliogr 2012; 103: 301-307.
125. Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics 2002; 2: 215-221.
126. Web page Alfred http://alfred.med.yale.edu/.